Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Richard G. Hahn"'
Autor:
Robert T. Eagan, Harry F. Bisel, Jesse L. Steinfeld, John H. Edmonson, David L. Ahmann, William R. Taylor, Richard G. Hahn, Douglass C. Tormey
Publikováno v:
Cancer. 36:1925-1935
Ninety patients with advanced breast cancer received a polychemotherapeutic program composed of 5-fluorouracil, cyclophosphamide, and prednisone with or without vincristine as a control group in a series of four consecutive Phase II clinical trials o
Autor:
Myrto Lefkopoulou, Paul J. Catalano, Minaxi Jhawer, Daniel G. Haller, Richard G. Hahn, Jules E. Harris, Sridhar Mani
Publikováno v:
Investigational New Drugs. 24:447-454
Metastatic anal cancer is a rare disease in the Western hemisphere and current treatment modalities are not effective. In this study, patients with advanced epithelial cancer of the anal canal received MAP followed by Bleomycin and CCNU upon progress
Phase II study of ?2 interferon in the treatment of the chronic myeloproliferative disorders (E5487)
Autor:
Barbara W. Grant, Janice P. Dutcher, Martin M. Oken, John M. Bennett, John M. Kirkwood, Peter H. Wiernik, Haesook T. Kim, Arthur I. Radin, James A. Stewart, Richard G. Hahn
Publikováno v:
Cancer. 98:100-109
BACKGROUND In vitro and clinical data suggest a therapeutic role for α2 interferon (IFN) in the treatment of the chronic myeloproliferative disorders. Accordingly, a multiinstitutional, Phase II trial of IFN in patients with agnogenic myeloid metapl
Autor:
Kathleen J. Propert, Jonathan Fleischmann, Richard G. Hahn, J. Edson Pontes, George Wilding, Donald L. Trump, Edward M. Messing, Judith Manola, E. David Crawford
Publikováno v:
Journal of Clinical Oncology. 21:1214-1222
Purpose: To evaluate the role of adjuvant interferon alfa after complete resection of locally extensive renal cell carcinoma. Patients and Methods: A total of 283 eligible patients with pT3–4a and/or node-positive disease were randomly assigned aft
Autor:
Richard G. Hahn, Lawrence H. Einhorn, Paul Elson, Richard D. Williams, Patrick J. Loehrer, Robert Dreicer, Craig R. Nichols
Publikováno v:
Journal of Clinical Oncology. 12:483-488
PURPOSE This multicenter cooperative group phase I/II trial evaluated the toxicity and efficacy of escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) with recombinant human granulocyte colony-stimulating factor (rhG-CS
Autor:
Paul Chervenick, Michael J. O'Connell, Janet Andersen, Richard G. Hahn, Stephanie Gregory, Leo I. Gordon, Joseph Mazza
Publikováno v:
Cancer. 71:464-470
Background The epidophyllotoxin VM 26 has been shown to have single-agent activity in patients with diffuse aggressive lymphoma. In an attempt to determine its activity in combination with other agents known to be effective in lymphoma, a Phase II tr
Autor:
Richard G. Hahn, Roscoe F. Morton, Shreyaskumar Patel, James E. Krook, Donald I. Twito, James A. Mailliard, Terry M. Therneau, John A. Laurie, Harold E. Windschitl
Publikováno v:
Cancer. 69:1440-1444
One hundred forty-two patients with progressive, hormonally refractory advanced prostate carcinoma who had not received prior chemotherapy were randomized to receive either combination chemotherapy with 5-fluorouracil (5-FU), doxorubicin, and mitomyc
Publikováno v:
New England Journal of Medicine. 326:519-523
The combination of streptozocin and fluorouracil has become the standard therapy for advanced islet-cell carcinoma. However, doxorubicin has also been shown to be active against this type of tumor, as has chlorozotocin, a drug that is structurally si
Autor:
Fernando J. Quevedo, Richard G. Hahn
Publikováno v:
Mayo Clinic Proceedings. 75:666-668
Autor:
Carol M. Van Haelst‐Pisani, Richard G. Hahn, John H. Edmonson, Herbert M. Reiman, Jan C. Buckner, Daniel J. Schaid
Publikováno v:
Cancer. 68:2354-2358
To assess whether chemosensitivity in metastatic soft tissue sarcoma (STS) is influenced by the histologic grade of the tumor, the authors retrospectively analyzed tumor responses to doxorubicin-based chemotherapy in four prospective studies conducte